@col69
Sad that certain posters are lamenting the lack of peer reviewed evidence by Kurtzberg into IL2Ra inhibition.
https://academic.oup.com/stcltm/article/11/Supplement_1/S22/6692650?login=false
Oh whoops …this argument is starting to disintegrate in front of our eyes !
As for the Dream CHF trial… perhaps the more cerebral here will look at the durability of effect data just released in the full peer review …it is awesome. In my opinion, I think there is an extremely good case for accelerated approval in the RMAT designated LVAD category post the next FDA Heart meeting (“next quarter”?) If that were to happen , I believe that the share price might rise many multiple in weeks…and tenfold within a year.
Food for thought . OP
@col69Sad that certain posters are lamenting the lack of peer...
- There are more pages in this discussion • 51 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
-0.045(3.83%) |
Mkt cap ! $1.290B | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.19 | $1.12 | $12.16M | 10.69M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 50650 | $1.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.14 | 124897 | 8 |
View Market Depth
| Last trade - 16.10pm 08/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.13 |
Change
-0.045 ( 4.33 %) |
||||
| Open | High | Low | Volume | ||
| $1.17 | $1.17 | $1.12 | 1447014 | ||
| Last updated 15.59pm 08/05/2024 ? | |||||
| MSB (ASX) Chart |